A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

714

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

January 25, 2021

Study Completion Date

December 15, 2030

Conditions
Melanoma
Interventions
BIOLOGICAL

Relatlimab

Specified dose on specified day

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (127)

1090

Local Institution - 0035, Vienna

Local Institution - 0047, Brussels

1121

Local Institution - 0135, Buenos Aires

1199

Local Institution - 0004, Buenos Aires

1200

Local Institution - 0049, Brussels

1426

Local Institution - 0003, Buenos Aires

2060

Local Institution - 0042, North Sydney

2298

Local Institution - 0043, Waratah

2730

Local Institution - 0103, Herlev

3112

Local Institution - 0089, Tauranga

3240

Local Institution - 0125, Hamilton

4120

Local Institution - 0041, Greenslopes

4215

Local Institution - 0045, Southport

5000

Local Institution - 0104, Odense

5020

Local Institution - 0037, Salzburg

5042

Local Institution - 0133, Bedford Park

6150

Local Institution - 0044, Murdoch

8036

Local Institution - 0036, Graz

8200

Local Institution - 0105, Aarhus N

9000

Local Institution - 0048, Ghent

9012

Local Institution - 0090, Dunedin

10126

Local Institution - 0111, Turin

11526

Local Institution - 0064, Athens

13011

Local Institution - 0081, Marseille

15006

Local Institution - 0023, A Coruña

18103

Local Institution - 0019, Allentown

20007

Local Institution - 0012, Washington D.C.

20014

Local Institution - 0021, San Sabastian Gipuzkoa

20133

Local Institution - 0108, Milan

20520

Local Institution - 0101, Turku

21237

Local Institution - 0077, Baltimore

21287

Local Institution - 0120, Baltimore

21614

Local Institution - 0032, Buxtehude

23538

Local Institution - 0028, Lübeck

24127

Local Institution - 0109, Bergamo

28034

Local Institution - 0026, Madrid

28204

Local Institution - 0018, Charlotte

30342

Local Institution - 0038, Atlanta

30625

Local Institution - 0033, Hanover

32224

Local Institution - 0013, Jacksonville

32806

Local Institution - 0117, Orlando

33075

Local Institution - 0080, Bordeaux

33521

Local Institution - 0119, Tampere

33612

Local Institution - 0007, Tampa

35042

Local Institution - 0084, Rennes

35128

Local Institution - 0110, Padua

41009

Local Institution - 0022, Seville

45070

Local Institution - 0094, Zapopan

45147

Local Institution - 0027, Essen

46804

Local Institution - 0114, Fort Wayne

48109

Local Institution - 0015, Ann Arbor

50937

Local Institution - 0029, Cologne

52621

Local Institution - 0087, Ramat Gan

53100

Local Institution - 0107, Siena

54622

Local Institution - 0065, Thessaloniki

55407

Local Institution - 0009, Minneapolis

55905

Local Institution - 0011, Rochester

59000

Local Institution - 0085, Lille

60611

Local Institution - 0016, Chicago

64060

Local Institution - 0091, Monterrey

66421

Local Institution - 0074, Homburg / Saar

68167

Local Institution - 0072, Mannheim

69120

Local Institution - 0132, Heidelberg

69310

Local Institution - 0078, Pierre-Bénite

72076

Local Institution - 0131, Tübingen

75010

Local Institution - 0083, Paris

75246

Local Institution - 0076, Dallas

77030

Local Institution - 0008, Houston

77500

Local Institution - 0093, Cancún

80000

Local Institution - 0079, Amiens

80131

Local Institution - 0106, Napoli

81675

Local Institution - 0034, München

86000

Local Institution - 0082, Poitiers

90095

Local Institution - 0020, Los Angeles

90220

Local Institution - 0102, Oulu

91120

Local Institution - 0088, Jerusalem

91900

Local Institution - 0129, Veracruz

93105

Local Institution - 0116, Santa Barbara

93401

Coastal Integrative Cancer Care, San Luis Obispo

97080

Local Institution - 0031, Würzburg

97130

Local Institution - 0092, Mérida

99089

Local Institution - 0030, Erfurt

110321

Local Institution - 0095, Bogotá

115478

Local Institution - 0112, Moscow

200542

Local Institution - 0067, Craiova

350040

Local Institution - 0113, Krasnodar

400015

Local Institution - 0070, Cluj-Napoca

660133

Local Institution - 0127, Krasnoyarsk

700483

Local Institution - 0069, Iași

3109601

Local Institution - 0086, Haifa

85724-5024

Local Institution - 0010, Tucson

02215

Local Institution - 0014, Boston

Local Institution - 0134, Boston

C1280AEB

Local Institution - 0002, Capital Federal

4102-4200

Local Institution - 0005, Buenos Aires

30130-090

Local Institution - 0058, Belo Horizonte

90035-903

Local Institution - 0057, Porto Alegre

91350-200

Local Institution - 0061, Porto Alegre

96810-110

Local Institution - 0073, Santa Cruz do Sul

05651-901

Local Institution - 0063, São Paulo

20220-410

Local Institution - 0059, Rio de Janiro

01246-000

Local Institution - 0060, São Paulo

01509-010

Local Institution - 0062, São Paulo

B3H 2Y9

Local Institution - 0124, Halifax

K1H 8L6

Local Institution - 0068, Ottawa

M5G 2M9

Local Institution - 0128, Toronto

H3T 1E2

Local Institution - 0123, Montreal

H4A 3J1

Local Institution - 0075, Montreal

Unknown

Local Institution - 0001, Santiago

050030

Local Institution - 0096, Medellín

00290

Local Institution - 0100, Helsinki

06484

Local Institution - 0071, Quedlinburg

0310

Local Institution - 0121, Oslo

60-780

Local Institution - 0040, Poznan

02-781

Local Institution - 0039, Warsaw

 022328

Local Institution - 0066, Bucharest

08035

Local Institution - 0024, Barcelona

08036

Local Institution - 0025, Barcelona

413 45

Local Institution - 0098, Gothenburg

221 85

Local Institution - 0099, Lund

171 64

Local Institution - 0118, Solna

751 85

Local Institution - 0122, Uppsala

BS2 8ED

Local Institution - 0052, Bristol

G12 0YN

Local Institution - 0054, Glasgow

SA2 8QA

Local Institution - 0056, Swansea

SE1 9RT

Local Institution - 0051, London

IV2 3UJ

Local Institution - 0126, Inverness

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03470922 - A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | Biotech Hunter | Biotech Hunter